Financial Snapshot

Revenue
$1.311M
TTM
Gross Margin
Net Earnings
-$13.51M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
728.4%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
$3.636M
Q3 2024
Book Value
$23.26M
Q3 2024
Cash
Q3 2024
P/E
-1.251
Nov 29, 2024 EST
Free Cash Flow
-$13.80M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $583.2K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $583.2K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $8.428M $20.97M $13.55M $14.93M $8.590M $2.290M $2.460M
YoY Change -59.81% 54.75% -9.24% 73.81% 275.11% -6.91%
% of Gross Profit
Research & Development $7.627M $16.40M $23.90M $37.88M $20.95M $14.19M $13.39M
YoY Change -53.5% -31.36% -36.92% 80.8% 47.64% 5.97%
% of Gross Profit
Depreciation & Amortization $7.050K $4.403K $12.83K $28.83K $11.13K $10.00K $10.00K
YoY Change 60.12% -65.68% -55.51% 159.16% 11.26% 0.0%
% of Gross Profit
Operating Expenses $16.06M $113.4M $37.45M $52.81M $29.54M $16.49M $15.85M
YoY Change -85.84% 202.81% -29.09% 78.75% 79.16% 4.04%
Operating Profit -$15.47M -$113.4M -$37.45M
YoY Change -86.36% 202.81%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $1.185M $448.7K $1.648K $222.7K $156.4K $960.0K $660.0K
YoY Change 164.16% 27124.94% -99.26% 42.41% -83.71% 45.45%
% of Operating Profit
Other Income/Expense, Net $1.185M $730.2K $319.1K -$667.6K $1.484M
YoY Change 62.31% 128.87% -147.79% -144.97%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$14.29M -$112.7M -$37.13M -$53.48M -$28.06M -$15.53M -$15.19M
YoY Change -87.32% 203.45% -30.58% 90.59% 80.68% 2.24%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.29M -$112.7M -$37.13M -$53.48M -$28.06M -$15.53M -$15.19M
YoY Change -87.32% 203.45% -30.58% 90.59% 80.68% 2.24%
Net Earnings / Revenue -2449.59%
Basic Earnings Per Share -$3.95 -$67.99 -$1.74 -$2.53 -$4.67
Diluted Earnings Per Share -$3.95 -$68.16 -$1.74 -$2.53 -$4.67 -$808.4K -$790.7K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $21.61M $28.79M $53.08M $89.00M $130.1M $65.70M $24.40M
YoY Change -24.94% -45.76% -40.36% -31.59% 98.02% 169.26%
Cash & Equivalents $21.61M $28.79M $53.08M $89.00M $130.1M $65.70M $24.40M
Short-Term Investments
Other Short-Term Assets $914.3K $1.367M $3.508M $3.400M $3.000M $300.0K $300.0K
YoY Change -33.11% -61.04% 3.19% 13.33% 900.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.52M $30.15M $56.58M $92.40M $133.0M $66.00M $24.70M
YoY Change -25.31% -46.71% -38.76% -30.53% 101.52% 167.21%
Property, Plant & Equipment $88.36K $2.320K $209.7K $400.0K $600.0K $0.00 $0.00
YoY Change 3708.62% -98.89% -47.58% -33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $40.72K $0.00 $29.37K $0.00 $0.00 $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $129.1K $2.320K $239.1K $400.0K $600.0K $0.00 $100.0K
YoY Change 5463.36% -99.03% -40.24% -33.33% -100.0%
Total Assets $22.65M $30.16M $56.82M $92.80M $133.6M $66.00M $24.80M
YoY Change
Accounts Payable $1.670M $842.8K $1.773M $4.500M $2.200M $1.700M $1.700M
YoY Change 98.2% -52.47% -60.6% 104.55% 29.41% 0.0%
Accrued Expenses $2.186M $2.358M $5.543M $10.80M $6.900M $3.100M $2.600M
YoY Change -7.3% -57.46% -48.67% 56.52% 122.58% 19.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.386M $3.201M $7.317M $15.30M $9.100M $4.900M $4.300M
YoY Change 37.0% -56.25% -52.18% 68.13% 85.71% 13.95%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $100.0K $300.0K
YoY Change -100.0% -66.67%
Total Long-Term Liabilities $0.00 $0.00 $0.00 $100.0K $300.0K $0.00 $0.00
YoY Change -100.0% -66.67%
Total Liabilities $4.386M $3.201M $7.317M $15.40M $9.400M $4.900M $4.300M
YoY Change 37.0% -56.25% -52.49% 63.83% 91.84% 13.95%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 3.618M 1.657M 21.29M 21.13M 6.002M
Diluted Shares Outstanding 3.618M 1.657M 21.29M 21.13M 6.002M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $16.903 Million

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2019-10-03. The firm's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. The company has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received United States Food and Drug Administration (FDA) clearance of its IND. The company has an early-stage program that is in the lead optimization stage, for an undisclosed DDR target. The firm is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute.

Industry: Pharmaceutical Preparations Peers: Aridis Pharmaceuticals, Inc. AXIM BIOTECHNOLOGIES, INC. Old Ayala, Inc bioAffinity Technologies, Inc. Vyant Bio, Inc. GYRE THERAPEUTICS, INC. Innovation Pharmaceuticals Inc. Cyclo Therapeutics, Inc. Cyclacel Pharmaceuticals, Inc.